Amphastar posts Jefferies healthcare conference deck highlighting pipeline shift toward proprietary drugs and biosimilars

Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc

AMPH

0.00
  • Amphastar outlined a shift toward higher-value assets, targeting 85% of its pipeline in proprietary drugs or biosimilars by 2026.
  • Pipeline mix projected at 50% proprietary, 35% biosimilar, 15% generic; compared with 2021 at 21% proprietary, 16% biosimilar, 63% generic.
  • Revenue of 720 in 2025; GAAP net income of 98.1; adjusted net income of 156.6; adjusted net income margin of 21.8%.
  • R&D spending expected to rise as focus shifts to proprietary products; cited 369 self-funded R&D investment over five years.
  • Key pipeline timing: AMP-018 launch expected in 2027; AMP-004 launch expected in 2027; AMP-007 launched April 2026; AMP-015 launched December 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.